News coverage about MabVax Therapeutics (NASDAQ:MBVX) has trended positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MabVax Therapeutics earned a news sentiment score of 0.26 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.3214594255368 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of MabVax Therapeutics (NASDAQ MBVX) traded down $0.05 during trading on Monday, hitting $0.82. 440,065 shares of the company traded hands, compared to its average volume of 248,804. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.54 and a quick ratio of 0.54. MabVax Therapeutics has a 52 week low of $0.43 and a 52 week high of $4.25.

MabVax Therapeutics (NASDAQ:MBVX) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($0.54) earnings per share (EPS) for the quarter. equities research analysts expect that MabVax Therapeutics will post -3.01 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://theolympiareport.com/2017/12/04/favorable-media-coverage-somewhat-unlikely-to-affect-mabvax-therapeutics-mbvx-share-price.html.

MabVax Therapeutics Company Profile

MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.

Insider Buying and Selling by Quarter for MabVax Therapeutics (NASDAQ:MBVX)

Receive News & Ratings for MabVax Therapeutics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MabVax Therapeutics Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.